Evidence map›Paper›PMID 32738506›Full record

ReviewNeurobiology of disease2020

It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Brendan P Lucey

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06322524 (Shanxi Key Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental Disorder), which is not on this map. Cited by 102 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06322524 completednot on this mapstarted 2021, after this paper: background citation

Shanxi Key Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental Disorder

TypeobservationalSponsorThe First Affiliated Hospital of Shanxi Medical UniversityRan2021 to 2022Enrolled37ConditionsSleep Quality, Sleep Duration, Sleep Onset LatencyArmsGamma sensory flicker
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 3 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  11. Article
  12. Characterizing circadian rest-activity rhythm patterns across Alzheimer's disease continuum in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  14. Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  15. Article
  16. Article
  17. Night-to-night rapid eye movement sleep variability: A relevant marker of early amyloid-β deposition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Observational
  18. Review
  19. Wake-promoting neuromodulators in Alzheimer's disease: Implications for sleep and brain clearance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Brendan P LuceyDepartment of Neurology, Washington University School of Medicine, St Louis, MO, United States of America; Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, United States of America. Electronic address: luceyb@wustl.edu.
Washington University in St. Louis · US

Funding

SLEEP QUALITY AND HUMAN AMLYOID-BETA KINETICSK76AG054863 · NIA · WASHINGTON UNIVERSITY · PI LUCEY, BRENDAN PATRICK · 2016 to 2020
$982k
NIA NIH HHS K76 AG054863
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by an asymptomatic period of amyloid-β (Aβ) deposition as insoluble extracellular plaque, intracellular tau aggregation, neuronal and synaptic loss, and subsequent cognitive dysfunction and dementia. A growing public health crisis, the worldwide prevalence of AD is expected to rise from 46.8 million individuals affected in 2015 to 131.5 million in 2050. Sleep disturbances have been associated with increased future risk of AD. A bi-directional relationship is hypothesized between sleep and AD with sleep disturbances as either markers for AD pathology and/or a mechanism mediating increased risk of AD. In this review, the evidence in humans supporting this complex relationship between sleep and AD will be discussed as well as the therapeutic potential and challenges of treating sleep disturbances to prevent or delay the onset of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCircadian RhythmCognitive DysfunctionHumansSleepSleep Wake Disorderstau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimer's diseaseAmyloid-betaSleepTau

Identifiers

PMID32738506
PMCPMC7484285
OpenAlexW3045713553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.